• Mashup Score: 1

    Dr. Sitra Tauscher-Wisniewski, from Novartis Gene Therapies, discusses long-term data for onasemnogene abeparvovec (Zolgensma), an FDA-approved gene therapy for SMA.

    Tweet Tweets with this article
    • Sitra Tauscher-Wisniewski, MD, Vice President of Clinical Development & Analytics at Novartis Gene Therapies, discusses long-term data for onasemnogene abeparvovec (Zolgensma), an FDA-approved gene therapy for spinal muscular atrophy #SMA @SMA_UK_ https://t.co/T7qSPC26Mi

  • Mashup Score: 0

    Dr. Sitra Tauscher-Wisniewski, from Novartis Gene Therapies, discusses the importance of early diagnosis of spinal muscular atrophy (SMA).

    Tweet Tweets with this article
    • Sitra Tauscher-Wisniewski, MD, Vice President of Clinical Development & Analytics at Novartis Gene Therapies, discusses the importance of early spinal muscular atrophy #SMA diagnosis #checkrare #rarediseases @SMA_UK_ https://t.co/OS6miI4WZT

  • Mashup Score: 0

    Dr. Sitra Tauscher-Wisniewski, from Novartis Gene Therapies, discusses long-term data for onasemnogene abeparvovec (Zolgensma), an FDA-approved gene therapy for SMA.

    Tweet Tweets with this article
    • Sitra Tauscher-Wisniewski, MD, Vice President of Clinical Development & Analytics at Novartis Gene Therapies, discusses long-term data for onasemnogene abeparvovec (Zolgensma), an FDA-approved gene therapy for spinal muscular atrophy #SMA @SMA_UK_ https://t.co/T7qSPC26Mi

  • Mashup Score: 0

    Dr. Sitra Tauscher-Wisniewski, from Novartis Gene Therapies, discusses the importance of early diagnosis of spinal muscular atrophy (SMA).

    Tweet Tweets with this article
    • Sitra Tauscher-Wisniewski, MD, Vice President of Clinical Development & Analytics at Novartis Gene Therapies, discusses the importance of early spinal muscular atrophy #SMA diagnosis #checkrare #rarediseases @SMA_UK_ https://t.co/OS6miI4WZT

  • Mashup Score: 0

    Dr. Sitra Tauscher-Wisniewski, from Novartis Gene Therapies, discusses long-term data for onasemnogene abeparvovec (Zolgensma), an FDA-approved gene therapy for SMA.

    Tweet Tweets with this article
    • Sitra Tauscher-Wisniewski, MD, Vice President of Clinical Development & Analytics at Novartis Gene Therapies, discusses long-term data for onasemnogene abeparvovec (Zolgensma), an FDA-approved gene therapy for spinal muscular atrophy #SMA @SMA_UK_ https://t.co/T7qSPC26Mi